Stock CMMB CHEMOMAB THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
1.29 USD +4.03% Intraday chart for Chemomab Therapeutics Ltd. +35.79% +152.94%
May. 06 Oppenheimer Upgrades Chemomab Therapeutics to Outperform MT
Apr. 10 Transcript : Chemomab Therapeutics Ltd. - Special Call

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
GL
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
AQ
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
AQ
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
GL
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GL
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GL
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
AQ
Oppenheimer Upgrades Chemomab Therapeutics to Outperform
MT
Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company’s annual general meeting of the shareholders (the “Meeting”) to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting - Form 6-K
PU
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
GL
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
GL
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
AQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
GL
Transcript : Chemomab Therapeutics Ltd. - Special Call
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
GL
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
AQ
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
GL
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
AQ
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
AQ
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMMB Stock
  4. News Chemomab Therapeutics Ltd.